42.70
-1.38(-3.13%)
Currency In USD
| Previous Close | 44.08 |
| Open | 44.01 |
| Day High | 45.05 |
| Day Low | 41.97 |
| 52-Week High | 57.99 |
| 52-Week Low | 24.1 |
| Volume | 1.38M |
| Average Volume | 1.24M |
| Market Cap | 4.38B |
| PE | -9.43 |
| EPS | -4.53 |
| Moving Average 50 Days | 49.6 |
| Moving Average 200 Days | 38.66 |
| Change | -1.38 |
If you invested $1000 in Crinetics Pharmaceuticals, Inc. (CRNX) since IPO date, it would be worth $1,742.15 as of February 15, 2026 at a share price of $42.7. Whereas If you bought $1000 worth of Crinetics Pharmaceuticals, Inc. (CRNX) shares 5 years ago, it would be worth $2,724.95 as of February 15, 2026 at a share price of $42.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
GlobeNewswire Inc.
Feb 05, 2026 9:05 PM GMT
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, B
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GlobeNewswire Inc.
Jan 26, 2026 10:00 PM GMT
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company mana
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
GlobeNewswire Inc.
Jan 22, 2026 9:05 PM GMT
First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents with classic CAHSAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today